Dermatological toxicity associated with the use of chemotherapy: hand foot syndrome an integrative approach
DOI:
https://doi.org/10.33448/rsd-v10i12.20501Keywords:
Cancer; Chemotherapy; Hand foot syndrome.Abstract
The objective was to identify the development of Hand-Foot Syndrome in the literature, as an adverse effect of the use of chemotherapy. Integrative review performed in LILACS, BDENF, PubMed and ScienceDirect databases, in Portuguese, English and Spanish. Clinical trials published with a time frame from 2016 to 2021 centered on the adult audience were selected and segregated into two topics. The information was tabulated in Microsoft Excel® 2010 program and processed based on the strategy: simple descriptive arithmetic mean, absolute and relative frequency. A total of 559 articles were found, after applying the inclusion and exclusion criteria, 20 studies were chosen to compose the final sample. The pharmacological class most listed as a potentiator of SMP was fluoropyrimidines (80%). Through the clinical manifestations presented in the syndrome, negative impacts perpetuate the routine of patients, as the performance of activities of daily living is compromised, to minimize the damage caused by this condition, therapeutic methods were highlighted, these are applied to reduce the degrees of the syndrome and better quality of life. In summary, it is clear that the use of chemotherapy increases overall and disease-free survival, however it causes some recurrent adverse reactions, including the Hand-Foot Syndrome, its manifestations are not life-threatening, but the limitations triggered infer damages to the self-care and quality of life becomes unsatisfactory.
References
Brasil (2016). Resolução Nº 510, DE 07 DE ABRIL DE 2016: Dispõe sobre as normas aplicáveis a pesquisas em Ciências Humanas e Sociais cujos procedimentos metodológicos envolvam a utilização de dados. Conselho Nacional de Saúde.
Caccavale, S., & Ruocco, E. (2017). Acral manifestations of systemic diseases: Drug-induced and infectious diseases. Clinics in dermatology, 35(1), 55-63.
Camera, S., Deleporte, A., Bregni, G., Trevisi, E., Pretta, A., Telli, T. A., & Hendlisz, A. (2020). Momentum: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. Clinical Colorectal Cancer, 19(4), 311-318.
Chang, W. T., Lu, S. N., Rau, K. M., Huang, C. S., & Lee, K. T. (2018). Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. The Kaohsiung journal of medical sciences, 34(7), 391-399.
Charalambous, A., Tsitsi, T., Astras, G., Paikousis, L., & Filippou, E. (2021). A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD). European Journal of Oncology Nursing, 50, 101866.
Conselho Federal de Enfermagem (1998). Resolução n. 210, de 1º junho de 1998. Dispõe sobre a atuação dos profissionais de Enfermagem que trabalham com quimioterápicos antineoplásicos. Rio de Janeiro.
Conselho Federal de Enfermagem (2001). Resolução n. 257, de 12 de julho de 2001. Acrescenta dispositivo ao Regulamento aprovado pela Resolução COFEN 210/1998, facultando ao enfermeiro o preparo de drogas quimioterápicas antineoplásicas.
Costa, J. S., Silva, G. M., Kameo, S. Y., Amorim, B. F., & Ramos, M. J. O. (2019). Síndrome Mão-Pé Induzida por Quimioterapia: Abordagem Clínica e Epidemiológica de Pacientes com Câncer. Revista Brasileira de Cancerologia, 65(2).
de Sousa, L. M. M., Marques-Vieira, C. M. A., Severino, S. S. P., & Antunes, A. V. (2017). A metodologia de revisão integrativa da literatura em enfermagem. Nº21 Série 2-Novembro 2017, 17.
de Souza Machado, C., de Souza Machado, L. F., Hörner, C., Dalla Nora, M., da Rosa, T. F., & Horner, R. (2018). Análise da toxicidade de uma Fluoropirimidina em Protocolo Quimioterápico. Saúde (Santa Maria), 3(44).
Delaloge, S., Piccart, M., Rutgers, E., Litière, S., van’t Veer, L. J., van den Berkmortel, F., & Cardoso, F. (2020). Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial. Journal of Clinical Oncology, 38(11), 1186.
Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., & Gianni, L. (2017). Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology, 18(6), 732-742.
Falcone, G., Arrigoni, C., Dellafiore, F., Gallucci, F., Milani, V., Boveri, S., & Caruso, R. (2019). A systematic review and Meta-analysis on the association between Hand-Foot Syndrome (HFS) and Cancer Chemothe.
Goebell, P. J., Müller, L., Hurtz, H. J., Koska, M., Busies, S., & Marschner, N. (2016). A cross-sectional investigation of fatigue, mucositis, hand-foot syndrome and dysgeusia in advanced renal cell carcinoma treatment: final results from the famous study. Clinical genitourinary cancer, 14(1), 63-68.
Haas, Naomi B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double- blind, placebo-controlled, randomised, phase 3 trial. The Lancet, 387(10032), 2008-2016.
Hartweg, D. (1991). Dorothea Orem: Self-care deficit theory (Vol. 4). Sage publications.
Haynes, D., & Ortega-Loayza, A. G. (2020). Adverse cutaneous reactions to chemotherapeutic drugs. Clinics in Dermatology, 38(6), 712- 728.
Hsu, Y. H., Shen, W. C., Wang, C. H., Lin, Y. F., & Chen, S. C. (2019). Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy. European Journal of Oncology Nursing, 43, 101670.
Hwang, I. G., Ji, J. H., Kang, J. H., Lee, H. R., Lee, H. Y., Chi, K. C., & Kang, W. K. (2017). A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Journal of geriatric oncology, 8(3), 170-175.
Instituto Nacional de Câncer José Alencar Gomes da Silva (2020). ABC do câncer: abordagens básicas para o controle do câncer. (6a ed.).
Instituto Nacional de Câncer José Alencar Gomes da Silva (2019). Estimativa 2020: incidência de câncer no Brasil.
Instituto Nacional de Câncer José Alencar Gomes da Silva (2008). Procedimentos e Cuidados Especiais. In: Ações de enfermagem para o controle do câncer: uma proposta de integração ensino-serviço. (3a ed.), (411) – (437).
Jehn, C. F., Hemmati, P., Lehenbauer-Dehm, S., Kümmel, S., Flath, B., & Schmid, P. (2016). Biweekly pegylated liposomal doxorubicin (Caelyx) in heavily pretreated metastatic breast cancer: a phase 2 study. Clinical breast cancer, 16(6), 514-519.
Karimi, E., Gharib, B., Rostami, N., Navidpour, L., & Afshar, M. (2019). Eficácia clínica de uma formulação tópica polifarbal no tratamento da síndrome mão-pé associada ao fluorouracil. Journal of Herbal Medicine, 17, 100270.
Komatsu, H., Yagasaki, K., Hirata, K., & Hamamoto, Y. (2019). Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study. European Journal of Oncology Nursing, 38, 65-69.
Kwakman, J. J., Simkens, L. H., van Rooijen, J. M., van de Wouw, A. J., Ten Tije, A. J., Creemers, G. J. M., ... & Punt, C. J. (2017). Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Annals of Oncology, 28(6), 1288-1293.
Lacouture, M., & Sibaud, V. (2018). Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. American journal of clinical dermatology, 19(1), 31-39.
Lokich, J. J., & Moore, C. (1984). Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Annals of internal medicine, 101(6), 798-800.
Li, F. F., Hong, C. H. E. N., & e Li, G. S. (2018). Chemotherapy-induced hand-foot syndrome in rectal cancer treated with acupuncture. World Journal of Acupuncture-Moxibustion , 28 (3), 151-155.
Masuda, N., Lee, S. J., Ohtani, S., Im, Y. H., Lee, E. S., Yokota, I., & Toi, M. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine, 376(22), 2147-2159.
Meulendijks, D., Cats, A., Beijnen, J. H., & Schellens, J. H. (2016). Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity–ready for clinical practice? Cancer treatment reviews, 50, 23-34.
National Institute Cancer. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. U.S (2009). Department of health and human services - National Institutes of Health, National Cancer Institute.
Nikolaou, V., Syrigos, K., & Saif, M. W. (2016). Incidence and implications of chemotherapy related hand-foot syndrome. Expert opinion on drug safety, 15(12), 1625-1633.
Ogawa, C., Morita, M., Omura, A., Noda, T., Kubo, A., Matsunaka, T., ... & Kudo, M. (2017). Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. Oncology, 93(Suppl. 1), 113-119.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica.
Reyes-Habito, C. M., & Roh, E. K. (2014). Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. Journal of the American Academy of Dermatology, 71(2), 203-e1.
Sanmartín, O., Beato, C., Suh-Oh, H. J., Aragón, I., España, A., Majem, M., & Grávalos, C. (2019). Manejo clínico de los eventos adversos cutáneos en pacientes tratados con quimioterapia: consenso nacional de la Academia Española de Dermatología y Venereología y de la Sociedad Española de Oncología Médica. Actas Dermo-Sifiliográficas, 110(6), 448-459.
Si, X., Zhang, L., Wang, H., Zhang, X., Wang, M., Han, B., & Jin, F. (2019). Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303. Thoracic cancer, 10(3), 551-556.
Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., & Guo, J. (2019). Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. Journal of Clinical Oncology, 37(32), 2987.
Suto, T., Ishiguro, M., Hamada, C., Kunieda, K., Masuko, H., Kondo, K., & Tomita, N. (2017). Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer. International journal of clinical oncology, 22(3), 494-504.
Xu, Y., Huang, Z., Lu, H., Yu, X., Li, Y., Li, W., & Fan, Y. (2019). Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. British journal of cancer, 121(8), 640-646.
Yap, Y. S., Kwok, L. L., Syn, N., Chay, W. Y., Chia, J. W. K., Tham, C. K., & Soong, R. C. T. (2017). Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine–induced hand-foot syndrome: a randomized clinical trial. JAMA oncology, 3(11), 1538-1545.
Zielinski, C., Láng, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., & Brodowicz, T. (2016). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. The Lancet Oncology, 17(9), 1230-1239.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Aislayne Rodrigues Valentim; Lays Santos Nascimento; Gustavo Venicius da Silva Santos ; Adão Renato de Jesus Freire ; Priscila Laíse dos Santos; Deyse Mirelle Souza Santos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
